What is it about?
Highlighting the intimate relationship between auto-inflammatory diseases and myeloproliferative neoplasia and demonstrating the dual-acting properties of JAK-inhibition: Myelosuppression and anti-inflammation.
Featured Image
Why is it important?
The potent anti-inflammatory properties of ruxolitinib make JAK-inhibitors a therapeutic option when treating non-malignant inflammatory diseases. This was most recently demonstrated by the effect on Graft-versus-Host-disease post transplant (both acute and chronic) where ruxolitinib "rescues" a significant proportion of corticosteroid-resistant cases, but has demonstrated efficacy in psoriasis (in a topical form).
Read the Original
This page is a summary of: The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms, Clinical Case Reports, May 2015, Wiley,
DOI: 10.1002/ccr3.281.
You can read the full text:
Contributors
The following have contributed to this page
